Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Comparison of baseline quality of life measures between renal cell carcinoma patients undergoing partial versus radical nephrectomy.

Arnold ML, Thiel DD, Diehl N, Wu KJ, Ames S, Parker AS.

BMC Urol. 2013 Oct 22;13:52. doi: 10.1186/1471-2490-13-52.

2.

Comparison of patient-reported quality of life outcome questionnaire response rates between patients treated surgically for renal cell carcinoma and prostate carcinoma.

Thiel DD, Davidiuk AJ, Broderick GA, Arnold M, Diehl N, Tavlarides A, Custer K, Parker AS.

BMC Urol. 2015 Jul 1;15:58. doi: 10.1186/s12894-015-0057-y.

3.

Quality of life after surgery for localized renal cell carcinoma: comparison between radical nephrectomy and nephron-sparing surgery.

Poulakis V, Witzsch U, de Vries R, Moeckel M, Becht E.

Urology. 2003 Nov;62(5):814-20.

PMID:
14624900
4.

Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma.

Gratzke C, Seitz M, Bayrle F, Schlenker B, Bastian PJ, Haseke N, Bader M, Tilki D, Roosen A, Karl A, Reich O, Khoder WY, Wyler S, Stief CG, Staehler M, Bachmann A.

BJU Int. 2009 Aug;104(4):470-5. doi: 10.1111/j.1464-410X.2009.08439.x. Epub 2009 Feb 23.

5.

Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy.

Leibovich BC, Blute M, Cheville JC, Lohse CM, Weaver AL, Zincke H.

J Urol. 2004 Mar;171(3):1066-70.

PMID:
14767272
6.
7.

Psycho-social well-being and general health status after surgical treatment for localized renal cell carcinoma.

Ficarra V, Novella G, Sarti A, Novara G, Galfano A, Cavalleri S, Artibani W.

Int Urol Nephrol. 2002;34(4):441-6.

PMID:
14577481
8.

Factors predicting health-related quality of life recovery in patients undergoing surgical treatment for renal tumors: prospective evaluation using the RAND SF-36 Health Survey.

Novara G, Secco S, Botteri M, De Marco V, Artibani W, Ficarra V.

Eur Urol. 2010 Jan;57(1):112-20. doi: 10.1016/j.eururo.2009.04.023. Epub 2009 Apr 21.

PMID:
19406562
9.

Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach.

Badalato GM, Kates M, Wisnivesky JP, Choudhury AR, McKiernan JM.

BJU Int. 2012 May;109(10):1457-62. doi: 10.1111/j.1464-410X.2011.10597.x. Epub 2011 Sep 20.

10.

Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma.

Hutterer GC, Patard JJ, Colombel M, Belldegrun AS, Pfister C, Guille F, Artibani W, Montorsi F, Pantuck AJ, Karakiewicz PI.

Cancer. 2007 Dec 1;110(11):2428-33.

12.
13.

Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer.

MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Dahm P, Canfield SE, McClinton S, Griffiths TR, Ljungberg B, N'Dow J; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel.

Eur Urol. 2012 Dec;62(6):1097-117. doi: 10.1016/j.eururo.2012.07.028. Epub 2012 Jul 20. Review.

PMID:
22841673
14.

A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.

Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Marechal JM, Klotz L, Skinner E, Keane T, Claessens I, Sylvester R; European Organization for Research and Treatment of Cancer (EORTC); National Cancer Institute of Canada Clinical Trials Group (NCIC CTG); Southwest Oncology Group (SWOG); Eastern Cooperative Oncology Group (ECOG).

Eur Urol. 2007 Jun;51(6):1606-15. Epub 2006 Nov 15.

PMID:
17140723
15.

Age distribution for partial and radical nephrectomy: whose nephrons are being spared?

von Klot C, Herrmann TR, Wegener G, Kuczyk MA, Hupe MC, Akkoyun M, Peters I, Kramer MW, Merseburger AS.

Adv Ther. 2013 Oct;30(10):924-32. doi: 10.1007/s12325-013-0061-0. Epub 2013 Oct 24.

PMID:
24155056
16.

Multiple ipsilateral renal tumors discovered at planned nephron sparing surgery: importance of tumor histology and risk of metachronous recurrence.

Blute M, Thibault GP, Leibovich BC, Cheville JC, Lohse CM, Zincke H.

J Urol. 2003 Sep;170(3):760-3.

PMID:
12913692
17.

Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment.

Crépel M, Jeldres C, Perrotte P, Capitanio U, Isbarn H, Shariat SF, Liberman D, Sun M, Lughezzani G, Arjane P, Widmer H, Graefen M, Montorsi F, Patard JJ, Karakiewicz PI.

Urology. 2010 Feb;75(2):271-5. doi: 10.1016/j.urology.2009.04.098. Epub 2009 Dec 4.

PMID:
19962740
18.

Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma.

Margulis V, Tamboli P, Jacobsohn KM, Swanson DA, Wood CG.

BJU Int. 2007 Dec;100(6):1235-9.

20.

Long-term outcome of multiple ipsilateral renal tumours found at the time of planned nephron-sparing surgery.

Krambeck A, Iwaszko M, Leibovich B, Cheville J, Frank I, Blute M.

BJU Int. 2008 Jun;101(11):1375-9. doi: 10.1111/j.1464-410X.2008.07588.x.

Supplemental Content

Support Center